Roth Capital Partners Facilitates CapsoVision's $27.5 Million IPO
CapsoVision, Inc. successfully launched its initial public offering with Roth Capital Partners as joint book-running manager, marking a significant milestone for the AI-powered medical technology sector.
Roth Capital Partners played a pivotal role as joint book-running manager in the initial public offering (IPO) of CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company specializing in AI-powered capsule endoscopy solutions. The IPO, which priced 5,500,000 shares of common stock at $5.00 per share, amassed gross proceeds of approximately $27.5 million before deductions. Trading commenced on the Nasdaq Capital Market under the ticker symbol 'CV' on July 2, 2025. Additionally, underwriters were granted a 30-day option to purchase up to an additional 825,000 shares at the IPO price. This development underscores the growing investor confidence in innovative medical technologies and the critical role of financial institutions like Roth Capital Partners in bridging the gap between groundbreaking companies and the capital markets.